Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if the study drug, PTK787, is safe and to find the
highest dose that can be given safely without causing serious side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Massachusetts General Hospital